CM
CCXI

Crestline Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Crestline Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-19,514
Closed -$257K – 251
2018
Q2 		$257K Buy
+19,514
New +$233K 0.03% 227

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Crestline Management's CCXI Position: Q3 2018 in Review

Crestline Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2018, closing a stake of 19,514 shares — an estimated $257K sold.

Crestline Management first reported a position in CCXI in Q2 2018 and held it in 1 quarter. The position peaked at $257K in Q2 2018. 106 funds tracked by Wall St. Rank hold CCXI as of Q3 2018.

  • Crestline Management reported no remaining ChemoCentryx, Inc. position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 19,514 ChemoCentryx, Inc. shares in Q3 2018, an estimated $257K.
  • Crestline Management first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 1 quarter.
  • Crestline Management's ChemoCentryx, Inc. position peaked at $257K in Q2 2018.
  • 106 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.